Tag Archives: chemotherapy
Drug Combination to Treat Cancer Expected to Rise
According to an article in the Wall Street Journal, combinations of drugs to treat cancer will be used more frequently in the future. Many studies presented at the 2011 annual meeting of the American Society of Clinical Oncology explored the … Continue reading
J&J withdraws application with FDA for new ovarian cancer drug
Johnson & Johnson, the owner of rights to Yondelis in the United States, has withdrawn its New Drug Application with the Food and Drug Administration for approval of the drug to treat ovarian cancer. The drug is being used in … Continue reading
Cost-Effective Analysis of Bevacizumab for Ovarian Cancer
A study published in the Journal of Clinical Oncology concludes that “[t]he addition of bevacizumab to standard chemotherapy in patients with advanced ovarian cancer is not cost effective.” The study analyzed costs of treating women with advanced ovarian cancer according … Continue reading
Carbo/Doxil in elderly patients
BACKGROUND: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients <70 years. PATIENTS AND METHODS: Nine hundred and seventy-six patients with … Continue reading
Phase II Trial of Phenoxodial Complete
INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we determined the safety and efficacy of intravenous phenoxodiol in combination … Continue reading
Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. Patients and methods: Patients with ovarian cancer that had … Continue reading
Chemosensitivity Assays for Ovarian Cancer
Point: Chemosensitivity Assays Have a Role in the Management of Recurrent Ovarian Cancer In this era of personalized medicine, patients with recurrent ovarian cancer deserve better than the 25% response rate that is associated with drugs selected based on clinical … Continue reading
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
Background: Because it is insufficiently clear whether BRCA-associated epithelial ovarian cancer (EOC) is more chemosensitive than sporadic EOC, we examined response to chemotherapy, progression-free survival (PFS) and overall survival (OS) in BRCA1- and BRCA2-associated versus sporadic EOC patients. Methods: Data … Continue reading
Randomized Phase III Clinical Trial Evaluating Weekly Cisplatin for Advanced Epithelial Ovarian Cancer
This randomized, open label, phase III clinical trial (1988–1992) compared the efficacy and safety of a dose-dense regimen of single-agent cisplatin with a standard 3-weekly schedule in first-line chemotherapy for advanced epithelial ovarian cancer. Two hundred eighty-five patients were randomly … Continue reading
Study examines end-of-life care for cancer patients
Many in their final days receive costly, aggressive treatments they may not want, according to researchers at the Dartmouth Atlas of Health Care. In California, Los Angeles County had the highest percentage of patients dying in hospitals. One in three … Continue reading
Posted in News
Also tagged cost of care, outcomes, quality of life, support, treatment
Leave a comment
Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study
Paclitaxel is one of the most common antitumour agents paclitaxel for the treatment of primary and relapsed ovarian cancer. Based on a German multicentre observational study, this article reflects the use of paclitaxe in German daily clinical practice. Patients and … Continue reading
